Clinical trial
Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee
NCT00371670 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00371670 |
|---|---|
| Title | Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee |
| Official title | A Phase II, 12-month, Double-blind, Placebo-controlled, Dose-finding, Multicenter Study to Evaluate the Safety, Tolerability, and Disease Modifying Efficacy of Daily Oral AAE581 (10, 25 and 50 mg Tablets) in Patients With Painful Knee Osteoarthritis, Kellgren-Lawrence Grade 3 by X-ray |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Knee Osteoarthritis |
| Intervention type | Drug |
| Interventions | balicatib (AAE581) |
| Enrollment | 223 |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2006 |
| First posted | Sep 4, 2006 |
| Last update posted | Mar 28, 2017 |
| Countries | Germany, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: